Expansion of capabilities provides customised bioconjugation solutions for Pharma and IVD industries. Biosynth, a supplier of critical raw materials to th...
Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of technologically advanced healthcare products and services, ...
FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter...
Under the terms for the line of credit, IGC can draw up to $1 million within a 30-day period. The interest rate for a draw is 1% plus the rate paid on cert...
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today...
The Centers for Medicare & Medicaid Services (CMS) announced broader Medicare coverage of LEQEMBI Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Nai...
Expands ResMed’s sleep management software solution, will help sleep labs and physicians more efficiently guide patients into and through diagnosis...
In phase I clinical trial, the single ascending doses (SAD) and multiple ascending doses (MAD) have been completed with ICP-488, demonstrating well-tolerat...
Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma® (onasemnogene abeparv...
-Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, today announced the identification of promising early le...
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon...
Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, has o...
Gadoquatrane is a highly stable contrast agent for magnetic resonance imaging (MRI) with high relaxivity and the potential of a substantially lower gadol...
Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage with global regulatory authorities to discuss nex...
© 2026 Biopharma Boardroom. All Rights Reserved.
